Home › Research › Topics › donepezil
donepezil
271 studies tagged donepezil, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
57/100
Taking more anticholinergic medications is associated with greater risk of hospitalization for confusion or dementia.
-
Cholinesterase inhibitors and memantine are able to stabilize or slow decline in cognition, function, behavior, and global change.
-
Between January 2006 and December 2010, 20,729 patients aged >70 years received a prescription for an AD medication.
-
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients.
-
47/100
The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of bullous pemphigoid (BP).
-
In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months.
-
Though these findings cannot prove causality, and we cannot rule out the possibility of residual confounding, they provide more evidence of the risk of using these drugs in older patients, reinforcing the concept that they should not be used in the absence of clear need.
-
The risk of dementia increases steadily with the number of medications used and age in older people in Taiwan.
-
In covariate-adjusted intent-to-treat analyses, haloperidol was associated with the highest mortality rates (relative risk=1.54, 95% confidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80).
-
STOPP criteria PIMs, unlike Beers criteria PIMs, are significantly associated with avoidable ADEs in older people that cause or contribute to urgent hospitalization.
-
38/100
Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008.
-
No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-ε4-negative or other analysis populations.
-
Delirium is a complex clinical syndrome characterised by disturbed consciousness, cognitive function, or perception.
-
Alzheimer’s disease (AD), a devastating neurodegenerative disorder, is the leading cause of dementia in the U.S. and in other developed countries.
-
The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs.
-
No statistically significant improvement in the primary outcome measures (MMSE and ADAS-Cog) was observed with drug therapy at 36 weeks, at which point all groups had lost, on average, 1 point on the MMSE and gained 2-3 points on the ADAS-Cog scale compared with baseline.
-
Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems.
-
The past 30 years have seen multiple attempts at demonstrating the safety and efficacy of drugs for Alzheimer's disease (AD), predominantly to improve symptoms.
-
Our findings suggest that long-term use of BZDs is associated with an increased risk for dementia, but the underlying mechanisms remain unclear, and further investigations are needed.
-
Patients completed a survey assessing statin-associated, cognitive-specific adverse drug reaction (ADR) characteristics, relation of the ADR to specific statin and dose (or potency), and time course of symptom onset and recovery.
-
14 studies were identified that matched inclusion criteria.
-
Use of cholinesterase inhibitors is associated with increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture in older adults with dementia.
-
This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
-
We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.
-
38/100
36% of practitioners reported not having used therapies for medical conditions other than dementia in patients with AD for reasons of limited compliance in these patients.
-
Although the warnings slowed the growth in the use of atypical antipsychotic drugs among patients with dementia, they did not reduce the overall prescription rate of these potentially dangerous drugs.
-
Inclusion criteria were early AD (mini-mental state examination [MMSE] score between 20 and 26 points or Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) score between 10 and 25 points), taking a stable dose of acetylcholinesterase inhibitor (donepezil, galantamine, or rivastigmine) for at least 4 months, a modified Hachinski score of 4 points or less, and CT or MRI results that were consistent with AD.
-
155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group).
-
Covarying for baseline scores, age, education, and duration of illness, the COMBO group had significantly lower mean annualized rates of deterioration in BDS and ADL scores compared with the CI (P<0.001; Cohen's dBDS=0.10-0.34 and dADL=0.23-0.46 at 1 to 2 y) and NO-RX groups (P<0.001; Cohen's dBDS=0.56-0.73 and dADL=0.32-0.48 at 1 to 2 y).
-
In 2004, estimated prevalence of ChI use among subjects with dementia ranged from 3.0% in the Netherlands to 20.3% in France.
-
In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor.
-
47/100
Sixty percent of the total patient group had baseline symptoms of agitation/aggression, delusions, or hallucinations on the NPI.
-
This paper considers the suitability of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) as the gold standard in registration trials of treatments for Alzheimer's disease.
-
Galantamine failed to significantly influence conversion to dementia.
-
Description The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia.
-
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine.
-
At weeks 12 and 24/28, ITT analysis demonstrated that memantine treatment produced statistically significant benefits over placebo treatment in NPI total score (p=0.001 and p=0.008), and in NPI single items: delusions (p=0.007 week 12, p=0.001 week 24/28), hallucinations (p=0.037 week 12), agitation/aggression (p=0.001 week 12, p=0.001 week 24/28), and irritability/lability (p=0.005 week 24/28), LOCF population.
-
In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease.
-
All ChEIs significantly improved cognitive and neuropsychiatric measures.
-
Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study drugs and 2090 patients on placebo, met the selection criteria.
-
The evidence base, although incomplete, suggests that modest treatment effect sizes are offset by risk of considerable adverse effects.
-
The target dose of 10 cm2 rivastigmine patch provides efficacy similar to the highest doses of capsules with a superior tolerability profile.
-
36/100
Donepezil hydrochloride is the most widely prescribed drug for Alzheimer's disease (AD).
-
43/100
Few ill health situations are more degrading to people of any age than loss of reasoning, faculties, and personhood.
-
Galantamine appears to be an effective and safe therapy for patients with DLB.
-
Care of dementia is extremely resource demanding and has a great impact on both the formal care systems and the situation for informal carers.
-
38/100
The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are the current mainstays in the drug treatment of Alzheimer's disease (AD).
-
Alzheimer's disease is the most common form of dementia in industrialized countries.
-
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
-
This study used administrative data from a large health care insurer in the southeast United States to describe the utilization pattern and health care outcomes of antipsychotic drug use in community-dwelling elders with dementia.
From across this tag
9 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Cognitive and Renal Outcomes of Finerenone in Older Adults With Heart Failure With Preserved Ejection Fraction: A Real-World Cohort Study
- Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With Dementia in the US
- A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease
- Rationales that Providers and Family Members Cited for the Use of Antipsychotic Medications in Nursing Home Residents with Dementia
- A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group
- Antidepressant Use at the Threshold: using electronic health records to characterise people prescribed antidepressants around the time of dementia diagnosis
- Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings
- A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
- Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors